Press coverage about ResMed (NYSE:RMD) has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. ResMed earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 46.0790718941246 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

RMD has been the subject of a number of research reports. Zacks Investment Research downgraded ResMed from a “hold” rating to a “sell” rating in a report on Tuesday, December 26th. BMO Capital Markets increased their price objective on ResMed to $82.00 and gave the stock a “market perform” rating in a report on Tuesday, December 12th. Macquarie downgraded ResMed from a “neutral” rating to a “sell” rating in a report on Tuesday, January 23rd. Finally, Northland Securities upgraded ResMed from an “under perform” rating to a “market perform” rating in a report on Tuesday, January 23rd. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $75.17.

How to Become a New Pot Stock Millionaire

RMD stock traded up $0.08 during trading hours on Friday, hitting $98.19. The company had a trading volume of 871,791 shares, compared to its average volume of 498,859. ResMed has a fifty-two week low of $67.04 and a fifty-two week high of $104.78. The company has a market capitalization of $14,034.00, a P/E ratio of 49.10 and a beta of 0.94.

ResMed (NYSE:RMD) last issued its quarterly earnings results on Monday, January 22nd. The medical equipment provider reported $1.00 EPS for the quarter, beating the consensus estimate of $0.78 by $0.22. ResMed had a return on equity of 22.75% and a net margin of 12.98%. The firm had revenue of $601.27 million during the quarter, compared to analysts’ expectations of $583.77 million. During the same period in the prior year, the firm posted $0.73 earnings per share. The business’s quarterly revenue was up 13.4% compared to the same quarter last year. sell-side analysts predict that ResMed will post 3.34 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, March 15th. Investors of record on Thursday, February 8th were given a dividend of $0.35 per share. The ex-dividend date of this dividend was Wednesday, February 7th. This represents a $1.40 annualized dividend and a yield of 1.43%. ResMed’s dividend payout ratio (DPR) is presently 70.00%.

In related news, CFO Brett Sandercock sold 1,250 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $84.99, for a total transaction of $106,237.50. Following the completion of the transaction, the chief financial officer now directly owns 78,322 shares of the company’s stock, valued at $6,656,586.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James Hollingshead sold 600 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $84.96, for a total value of $50,976.00. Following the transaction, the insider now directly owns 62,602 shares of the company’s stock, valued at $5,318,665.92. The disclosure for this sale can be found here. Insiders have sold 44,139 shares of company stock valued at $4,398,906 over the last three months. Insiders own 1.77% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2018/03/18/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-resmed-rmd-share-price.html.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.